TABLE 10-1 Diphtheria Toxoid–, Tetanus Toxoid–, and Acellular Pertussis–Containing Vaccines Licensed and Available in the United States

Vaccine Trade Name Manufacturer Dose (Presentation) Antigen Concentration Preservative Age Group Doses Route
DT No Trade Name Sanofi Pasteur, Inc 0.5 mL (single-dose vials) 6.7 LF diphtheria toxoid;
5 LF tetanus toxoid
≤ 0.3 μg Hg/0.5 mL dose 6 weeks–
6 years
3 or 4* Intramuscular
DT No Trade Name Sanofi Pasteur, Inc 0.5 ml- (single-dose vials) 25 LF diphtheria toxoid;
5 LF tetanus toxoid
0 6 weeks-
6 years
5 Intramuscular
DTaP Tripedia Sanofi Pasteur, Inc 0.5 ml- (single-dose vials) 6.7 LF diphtheria toxoid;
5 LF tetanus toxoid; 23.4 ug PT;
23.4 ug FHA
≤ 0.3 ug Hg/ 0.5 mL dosc 6 weeks-
6 years
5 Intramuscular
DTaP Infanrix GlaxoSmithKHnc Biological s 0.5 ml- (single-dose vials ) 25 LF diphtheria toxoid;
10 LF tetanus toxoid;
25 (ig pertussis toxin;
25 ug FHA; 8.0 ug pcrtactin
0 6 weeks-
6 years
5 Intramuscular
DTaP DAPTACEL Sanofi Pasteur, Ltd 0.5 ml- (single-dose vials) 15 LF diphtheria toxoid;
5 LF tetanus toxoid;
10 (ig pertussis toxin;
5ugFHA; 3 Mg PRN;
5 (Jg FIM
0 6 weeks-
6 years
5 Intramuscular


The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement